BEIGF:OTCMKTS
BeOne Medicines
US$ २१.९५
०.००%
(०.००) 1D
जुन ९, १२:४९:४६ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BEIGF...
Mkt. cap
४२.४० अरब
Avg. vol.
०.००
Volume
०.००
52-wk high
US$ २४.९२
52-wk low
US$ २१.९५
Beta
०.८४
Shares outstanding
१.४३ अरब
No. of employees
१२ हजार
Mkt. cap
४२.४० अरब
Avg. vol.
०.००
Volume
०.००
52-wk high
US$ २४.९२
52-wk low
US$ २१.९५
Beta
०.८४
Shares outstanding
१.४३ अरब
No. of employees
१२ हजार
News stories
From web sources and news partners
CNBC
·
१ घण्टा पहिले
Jim Cramer says the bull market's remarkable 4-year run offers a crucial lesson for investors
New York Post
·
१ घण्टा पहिले
NYSE's opening bell honors Italian Americans who beat stereotypes to reach pinnacle of finance
Simply Wall Street
·
३३ मिनेट पहिले
What Does Microsoft (MSFT) Gain From Its New Maia 300 AI Chip?
Reuters
·
२४ मिनेट पहिले
Nasdaq ends lower as oil prices surge ahead of earnings, economic data
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Employees१२ हजार
Founded२०१० अक्टोबर २८
Headquarters-
Sector-
Websitebeonemedicines.com